Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 4, 2014, Pages 489-497

  Solomon, Daniel H ^a   Kremer, Joel M ^b   Fisher, Mark ^c   Curtis, Jeffrey R ^d   Furer, Victoria ^g   Harrold, Leslie R ^e   Hochberg, Marc C ^f   Reed, George ^e   Tsao, Peter ^a   Greenberg, Jeffrey D ^g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d The University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; DMARDs; Epidemiology; Methotrexate; Rheumatoid arthritis

Indexed keywords

CANCER; DMARDS; EPIDEMIOLOGY; METHOTREXATE; RHEUMATOID ARTHRITIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASMS; RISK; SEX FACTORS; TREATMENT OUTCOME;

EID: 84894906316     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.08.003     Document Type: Article

References (41)

1. Isomaki H.A., Hakulinen T., Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978, 31(11):691-696.
2. Askling J., Fored C.M., Baecklund E., Brandt L., Backlin C., Ekbom A., et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005, 64(10):1414-1420.
3. Baecklund E., Ekbom A., Sparen P., Feltelius N., Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Br Med J 1998, 317(7152):180-181.
4. Mariette X., Cazals-Hatem D., Warszawki J., Liote F., Balandraud N., Sibilia J., et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002, 99(11):3909-3915.
5. Bleyer W.A. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 1977, 4(2):87-101.
6. Lipsky P.E., van der Heijde D.M., Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343(22):1594-1602.
7. Kremer J.M., Dougados M., Emery P., Durez P., Sibilia J., Shergy W., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52(8):2263-2271.
8. Smolen J.S., Aletaha D., Koeller M., Weisman M.H., Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370(9602):1861-1874.
9. FDA: Cancer Warnings Required for TNF Blockers. FDA Note to Correspondents 2009, FDA, [cited 2011 December 23]; Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175803.htm.
10. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295(19):2275-2285.
11. Bongartz T., Warren F.C., Mines D., Matteson E.L., Abrams K.R., Sutton A.J. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009, 68(7):1177-1183.
12. Thompson A.E., Rieder S.W., Pope J.E. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 2011, 63(6):1479-1485.
13. Askling J., Fahrbach K., Nordstrom B., Ross S., Schmid C.H., Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011, 20(2):119-130.
14. Leombruno J.P., Einarson T.R., Keystone E.C. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009, 68(7):1136-1145.
15. Wolfe F., Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007, 56(9):2886-2895.
16. Amari W., Zeringue A.L., McDonald J.R., Caplan L., Eisen S.A., Ranganathan P. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford) 2011, 50(8):1431-1439.
17. Simon T.A., Smitten A.L., Franklin J., Askling J., Lacaille D., Wolfe F., et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 2009, 68(12):1819-1826.
18. Schiff M.H., Kremer J.M., Jahreis A., Vernon E., Isaacs J.D., van Vollenhoven R.F. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2012, 13(5):R141.
19. Lopez-Olivo M.A., Tayar J.H., Martinez-Lopez J.A., Pollono E.N., Cueto J.P., Gonzales-Crespo M.R., et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012, 308(9):898-908.
20. Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharm Ther 2007, 82:143-156.
21. Kremer J.M. The CORRONA database. Autoimmun Rev 2006, 5(1):46-54.
22. Fisher M.C., Furer V., Hochberg M.C., Greenberg J.D., Kremer J., Curtis J.R., et al. Malignancy Validation in a United States Registry of Rheumatoid Arthritis Patients. BMC musculoskeletal disorders 2012, 13:85.
23. Aletaha D., Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005, 23(5 Suppl 39):S100-S108.
24. Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation. J Rheumatol 2001, 28(5):982-989.
25. Rosenbaum P.R., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70:41-55.
26. Glynn R.J., Schneeweiss S., Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006, 98(3):253-259.
27. Austin P.C., Mamdani M.M. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 2006, 25(12):2084-2106.
28. Askling J., van Vollenhoven R.F., Granath F., Raaschou P., Fored C.M., Baecklund E., et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?. Arthritis Rheum 2009, 60(11):3180-3189.
29. Setoguchi S., Solomon D.H., Weinblatt M.E., Katz J.N., Avorn J., Glynn R.J., et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. [erratum appears in Arthritis Rheum. 2006 Oct;54(10):3134]. Arthritis Rheum 2006, 54(9):2757-2764.
30. Wolfe F., Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007, 56(5):1433-1439.
31. Hazleman B. Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens. Am J Med 1985, 78(1A):39-43.
32. Kingsmore S.F., Hall B.D., Allen N.B., Rice J.R., Caldwell D.S. Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J Rheumatol 1992, 19(9):1462-1465.
33. Usman A.R., Yunus M.B. Non-Hodgkin's lymphoma in patients with rheumatoid arthritis treated with low dose methotrexate. J Rheumatol 1996, 23(6):1095-1097.
34. Kremer J.M. Is methotrexate oncogenic in patients with rheumatoid arthritis?. Semin Arthritis Rheum 1997, 26(6):785-787.
35. Herk-Sukel M.P., Lemmens V.E., Poll-Franse L.V., Herings R.M., Coebergh J.W. Record linkage for pharmacoepidemiological studies in cancer patients. Pharmacoepidemiol Drug Saf 2012, 21(1):94-103.
36. Askling J., Baecklund E., Granath F., Geborek P., Fored M., Backlin C., et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009, 68(5):648-653.
37. Bernatsky S., Clarke A., Suissa S. Lung cancer after exposure to disease modifying anti-rheumatic drugs. Lung Cancer 2008, 59(2):266-269.
38. Bernatsky S., Clarke A.E., Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008, 168(4):378-381.
39. Chakravarty E.F., Michaud K., Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005, 32(11):2130-2135.
40. Geborek P., Bladstrom A., Turesson C., Gulfe A., Petersson I.F., Saxne T., et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.[see comment]. Ann Rheum Dis 2005, 64(5):699-703.
41. Dixon W.G., Watson K.D., Lunt M., Mercer L.K., Hyrich K.L., Symmons D.P. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010, 62(6):755-763.